Christian Marin Müller

CEO | Speratum Biopharma

A Post-Doctoral Associate in the Department of Surgery at Baylor College of Medicine (BCM), in the laboratories of Dr. Qizhi Yao and Dr. Changyi Chen, with a focus on developing RNAi-based therapeutics for cancer treatment.

That work is the basis for Speratum, a preclinical-stage cancer therapy company with exclusive licenses for multiple technologies originally developed at BCM. At Speratum, we combine RNA interference (RNAi) and synthetic biology with a novel, polymeric nanoparticle-based delivery system. Our main focus is on the treatment of pancreatic and ovarian cancers. We are currently developing novel targeted antiviral applications of our technology.

Executive Director of Speratum since its foundation in 2014 with a Ph.D. in Molecular Virology and Microbiology from BCM, an MS in Entrepreneurial Biotechnology from the Science and Technology Entrepreneurship Program (STEP) at Case, and a BS in molecular biology from Florida Tech.

I have previously worked as a consultant to biotechnology start-up companies and governmental organizations. My work has contributed to developing projects ranging from medical devices to HIV research.

Founding member of the Scientific Ethics Committee for the Ministry of Health of Costa Rica, founding member of CRBiomed, the biomedical cluster of Costa Rica, and am a member of the Aspen Global Leadership Network (AGLN), the Aspen Institute, and the Central American Leadership Initiative (CALI).